on SENSORION (EPA:ALSEN)
Sensorion Unveils Promising New Clinical Advances
Sensorion Announces Positive New Clinical Data for its SENS-501 and SENS-401 Programs at the World Congress of Audiology in Paris. The results presented include significant advances in therapies targeting hearing loss.
Prof. Catherine Birman shared positive initial safety data for SENS-501 in a Phase 1/2 trial. Results show that the intervention is well tolerated, with no side effects observed.
Prof. Yann Nguyen announced preliminary results from the Phase 2a trial for the prevention of cisplatin-induced ototoxicity with SENS-401. The data show a favorable safety profile and a positive trend toward the drug’s otoprotective effect.
Additional analyses of SENS-401 also show clinical benefits in preserving residual hearing after cochlear implantation.
The full presentations are available on the Sensorion website.
R. H.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all SENSORION news